Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Biosyent ( (TSE:RX) ) has provided an update.
BioSyent Inc. has closed its previously announced acquisition of Oral Science Inc., a privately owned Canadian distributor of specialized dental hygiene and oral health products based in Brossard, Quebec. The $25.5 million deal, structured as an arm’s length share purchase, includes cash, BioSyent common shares subject to escrow and lock-up provisions, and potential contingent earn-out and royalty payments funded through internal cash and new bank facilities, and qualifies as an expedited acquisition pending final TSX Venture Exchange approval.
Oral Science, founded in 2003, brings a portfolio and integrated approach focused on diagnosis and monitoring, in-office treatments, home-care solutions and clinical education for conditions such as periodontal disease, high-risk caries, dry mouth and oral lesions. BioSyent also approved new grants of restricted share units to Oral Science and BioSyent employees, reinforcing long-term alignment as the company expands its oral health platform and deepens its presence in the Canadian dental market.
The most recent analyst rating on (TSE:RX) stock is a Buy with a C$16.50 price target. To see the full list of analyst forecasts on Biosyent stock, see the TSE:RX Stock Forecast page.
Spark’s Take on TSE:RX Stock
According to Spark, TipRanks’ AI Analyst, TSE:RX is a Outperform.
Biosyent’s overall stock score is driven by strong financial performance and positive technical indicators. The company’s robust revenue growth and profitability, combined with a positive market trend, support a favorable outlook. However, valuation metrics suggest the stock is fairly priced, and potential overbought conditions warrant caution.
To see Spark’s full report on TSE:RX stock, click here.
More about Biosyent
BioSyent Inc. is a Mississauga-based, growth-oriented specialty healthcare company listed on the TSX Venture Exchange under the symbol RX. It focuses on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products through its Canadian pharma, international pharma and oral health business units, targeting therapies that are safe, effective and improve patient outcomes.
Average Trading Volume: 4,857
Technical Sentiment Signal: Buy
Current Market Cap: C$181.2M
Learn more about RX stock on TipRanks’ Stock Analysis page.